JP2024073525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024073525A5 JP2024073525A5 JP2024037853A JP2024037853A JP2024073525A5 JP 2024073525 A5 JP2024073525 A5 JP 2024073525A5 JP 2024037853 A JP2024037853 A JP 2024037853A JP 2024037853 A JP2024037853 A JP 2024037853A JP 2024073525 A5 JP2024073525 A5 JP 2024073525A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition
- acid molecule
- mir
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- 108091086215 miR-379 stem-loop Proteins 0.000 claims description 9
- 108091023526 miR-541 stem-loop Proteins 0.000 claims description 9
- 108091007685 MIR541 Proteins 0.000 claims description 8
- 108091079015 miR-379 Proteins 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 25
- 108020004707 nucleic acids Proteins 0.000 claims 25
- 102000039446 nucleic acids Human genes 0.000 claims 25
- 239000002773 nucleotide Substances 0.000 claims 24
- 125000003729 nucleotide group Chemical group 0.000 claims 24
- 108020004414 DNA Proteins 0.000 claims 4
- 241000702421 Dependoparvovirus Species 0.000 claims 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 4
- 229920002873 Polyethylenimine Polymers 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 208000016097 disease of metabolism Diseases 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 238000007385 chemical modification Methods 0.000 claims 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims 2
- -1 cyclohexene nucleic acid Chemical class 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- LUTRZKIJGBTTPE-UHFFFAOYSA-N morpholin-4-yloxyphosphonamidic acid Chemical compound NP(O)(=O)ON1CCOCC1 LUTRZKIJGBTTPE-UHFFFAOYSA-N 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU100927 | 2018-09-11 | ||
| LULU100927 | 2018-09-11 | ||
| JP2020569736A JP7530836B2 (ja) | 2018-09-11 | 2019-09-10 | 代謝性疾患の処置において使用するためのマイクロｒｎａインヒビター |
| PCT/EP2019/074056 WO2020053186A1 (en) | 2018-09-11 | 2019-09-10 | Microrna inhibitors for use in treating metabolic diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569736A Division JP7530836B2 (ja) | 2018-09-11 | 2019-09-10 | 代謝性疾患の処置において使用するためのマイクロｒｎａインヒビター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024073525A JP2024073525A (ja) | 2024-05-29 |
| JP2024073525A5 true JP2024073525A5 (https=) | 2024-09-25 |
Family
ID=63998726
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569736A Active JP7530836B2 (ja) | 2018-09-11 | 2019-09-10 | 代謝性疾患の処置において使用するためのマイクロｒｎａインヒビター |
| JP2024037853A Pending JP2024073525A (ja) | 2018-09-11 | 2024-03-12 | 代謝性疾患の処置において使用するためのマイクロｒｎａインヒビター |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569736A Active JP7530836B2 (ja) | 2018-09-11 | 2019-09-10 | 代謝性疾患の処置において使用するためのマイクロｒｎａインヒビター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12584126B2 (https=) |
| EP (1) | EP3850099B1 (https=) |
| JP (2) | JP7530836B2 (https=) |
| CN (1) | CN112654705B (https=) |
| CA (1) | CA3103175A1 (https=) |
| DK (1) | DK3850099T3 (https=) |
| WO (1) | WO2020053186A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12584126B2 (en) | 2018-09-11 | 2026-03-24 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | microRNA inhibitors for use in treating metabolic diseases |
| CN111228291B (zh) * | 2020-03-20 | 2020-10-02 | 军事科学院军事医学研究院环境医学与作业医学研究所 | miR-541在制备抗神经元细胞缺氧损伤药物中的应用及药物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| WO2014074874A1 (en) * | 2012-11-09 | 2014-05-15 | Regents Of The University Of Minnesota | Osteosarcoma diagnostic and prognostic methods |
| EP2868746A1 (en) | 2013-10-29 | 2015-05-06 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Micrornas modulating the effect of glucocorticoid signaling |
| AU2015335923B2 (en) * | 2014-10-21 | 2021-04-29 | University Of Massachusetts | Recombinant AAV variants and uses thereof |
| CN106267207A (zh) * | 2015-06-05 | 2017-01-04 | 昆山彭济凯丰生物科技有限公司 | 通过miR-96进行减肥、降血糖和降血脂的方法和药物及其应用 |
| CN119033819A (zh) * | 2017-11-22 | 2024-11-29 | 迈索布拉斯特国际有限公司 | 细胞组合物及治疗方法 |
| US12584126B2 (en) | 2018-09-11 | 2026-03-24 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | microRNA inhibitors for use in treating metabolic diseases |
-
2019
- 2019-09-10 US US17/251,803 patent/US12584126B2/en active Active
- 2019-09-10 CN CN201980058818.XA patent/CN112654705B/zh active Active
- 2019-09-10 JP JP2020569736A patent/JP7530836B2/ja active Active
- 2019-09-10 CA CA3103175A patent/CA3103175A1/en active Pending
- 2019-09-10 WO PCT/EP2019/074056 patent/WO2020053186A1/en not_active Ceased
- 2019-09-10 EP EP19780152.5A patent/EP3850099B1/en active Active
- 2019-09-10 DK DK19780152.5T patent/DK3850099T3/da active
-
2024
- 2024-03-12 JP JP2024037853A patent/JP2024073525A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024073525A5 (https=) | ||
| US20140066491A1 (en) | Chemical modification motifs for mirna inhibitors and mimetics | |
| JP2005517427A5 (https=) | ||
| JP2005517438A5 (https=) | ||
| AU2019234917B2 (en) | Inhibitors of micro-RNA 22 | |
| JP2024112834A5 (https=) | ||
| JP2009535039A5 (https=) | ||
| US20240336919A1 (en) | Rna editing | |
| JP2020503014A5 (https=) | ||
| JP7793144B2 (ja) | 修飾ヘテロ核酸 | |
| US20220135972A1 (en) | Optimal ps modification pattern for heteronucleic acids | |
| JPWO2023041508A5 (https=) | ||
| US20250297253A1 (en) | Artificial rna molecule | |
| Dysko et al. | Covalently attached intercalators restore duplex stability and splice-switching activity to triazole-modified oligonucleotides | |
| EP4709862A2 (en) | Rnai targeting kif1a missense mutations for treatment of kif1a associated neurological disorder | |
| WO2022018155A1 (en) | Lna oligonucleotides for splice modulation of stmn2 | |
| JPWO2021002359A1 (ja) | 核酸医薬とその使用 | |
| CN115702243A (zh) | 用于治疗性多核苷酸的鸟苷类似物 | |
| WO2024186922A2 (en) | Compositions and methods for cell-type specific activation of therapeutic nucleic acids | |
| WO2024254243A2 (en) | Rnai targeting ppp2r5d missense mutations for treatment of jordan's syndrome | |
| CN121915029A (zh) | 靶向scn10a基因的aso及其应用 | |
| WO2024162453A1 (ja) | 一本鎖核酸及びその用途 | |
| JP2024546887A (ja) | オリゴヌクレオチドｇｂａアゴニスト | |
| CN121263524A (zh) | 能够上调葡糖脑苷脂酶表达的寡核苷酸 | |
| HK40111119A (zh) | 寡核苷酸gba激动剂 |